Fusen Pharmaceutical Company Limited
福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR LAUNCHING
"DOXAZOSIN MESYLATE EXTENDED-RELEASE TABLETS"
BEING ACCEPTED

The board of directors (the "**Board**") of Fusen Pharmaceutical Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the application for launching "Doxazosin Mesylate Extended-Release Tablets" developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited* (嘉亨(珠海橫琴)醫藥科技有限公司), a wholly-owned subsidiary of the Group, has been submitted to and accepted by the National Medical Products Administration of the People's Republic of China. "Doxazosin Mesylate Extended-Release Tablets" are used for the treatment of the following diseases: symptomatic treatment of benign prostatic hyperplasia, and hypertension.

"Doxazosin Mesylate Extended-Release Tablets" are selective α 1 receptor inhibitors. The pharmacological effects include the following: in the human body, doxazosin mesylate counteracts prostate contraction induced by phenylephrine (an α 1 receptor agonist), which reduces peripheral vascular resistance to lower blood pressure. Additionally, it reduces urethral resistance, which helps alleviate symptoms of benign prostatic hyperplasia and improves urine flow.

Benign prostatic hyperplasia (BPH) is a common and frequently-occurring disease among elderly men, with the incidence rate increasing with age. Epidemiological studies show that 40% of men experience prostatic hyperplasia after the age of 50, and this rate rises to nearly 90% by the age of 80, and it further increases by the age of 90.

China has nearly 300 million individuals with hypertension, making it a country with a high incidence of the condition. The overall incidence rate has reached 23.2%. In the northern regions, the incidence rate can reach 32%-33%.

Doxazosin Mesylate Tablets are classified as a Class B drug under the National Reimbursement Drug List, with no restrictions on medical insurance indications or types of diseases. They have become a first-line treatment for mild to moderate hypertension both domestically and internationally, as well as a first-line treatment for benign prostatic hyperplasia with associated lower urinary tract symptoms. The tablets offer several advantages: rapid onset of action, long-lasting effects, more stable release, significant efficacy, ease of use, and are unaffected by age or mild to moderate renal impairment. The "Doxazosin Mesylate Extended-Release Tablets" developed by the Company have been filed as Class 4 chemical drugs. The formulation is essentially the same as the reference drug, and the tablets have been proven to match the reference drug in quality and efficacy through pharmacological and clinical (BE) studies, which ensures the safety and efficacy of the medication for patients, with a risk-to-benefit ratio comparable to that of the reference drug.

"Doxazosin Mesylate Extended-Release Tablets" are another important product of the Group, which further enriches our product pipeline in the fields of urology and the circulatory system. Once launched, this product will provide additional treatment options for patients with benign prostatic hyperplasia and hypertension.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Changcheng
Chairman and Executive Director

Hong Kong, 8 August 2024

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Zhiming (formerly known as Mr. Cao Dudu) as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.

* *For identification purposes only*